Summary
Updated Aug 31, 2026
Deep Track Biotechnology Master Fund, Ltd. is 10% Owner of Attovia Therapeutics, Inc. (ATTO). 6 SEC Form 4 filings on record going back to 2025, most recently on 10 August 2026. Most recent open-market trade: bought $10.00M of LBRX on 16 September 2025. Lifetime open-market purchases: $60.00M. Lifetime open-market sales: $22.35M. Historical track record: 2/5 stars across 4 tracked purchases.
Recent Transactions
7Every recent SEC Form 4 transaction Deep Track Biotechnology Master Fund, Ltd. has reported, most recent first.
Track Record
InsiderAlpha computes a forward-return-based score for every insider with enough Form 4 purchase history. The metrics below reflect realized performance after each tracked open-market purchase.
| Metric | Value |
|---|---|
| InsiderAlpha rating | ★★☆☆☆ (2/5) |
| Total purchases tracked | 4 |
| Purchases with forward-return data | 4 |
| 30-day win rate | 50% |
| 90-day win rate | 100% |
| Avg 5-day return | -0.89% |
| Avg 30-day return | -1.08% |
| Avg 90-day return | +27.34% |
| Best 30-day return | +2.18% |
Trading Pattern
InsiderAlpha's records for Deep Track Biotechnology Master Fund, Ltd. go back to 2025: 6 primary Form 4 filings, an average of 3.0 per year. The typical open-market purchase is $12.00M (5 buys totaling $60.00M). The largest single buy on record is $30.00M of LBRX in 2025. Sales side: 2 recorded sales totaling $22.35M, so the filing history runs buy-heavy by dollar value. No transaction on record carries a Rule 10b5-1 flag - the filings look discretionary rather than pre-scheduled, which makes their timing more informative as a signal.
Other Insiders Active in the Same Stocks
Insiders who reported open-market trades in the last 12 months at the companies Deep Track Biotechnology Master Fund, Ltd. files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- GOLDMAN SACHS GROUP INC - $27.32M of ATTO open-market activity in the last 12 months
- Colin Walsh - $27.32M of ATTO open-market activity in the last 12 months
- Ran Nussbaum - $15.00M of LBRX open-market activity in the last 12 months
- Pontifax Management 4 G.P. (2015) Ltd. - $15.00M of LBRX open-market activity in the last 12 months
- Redmile Group, LLC - $10.20M of ATTO open-market activity in the last 12 months
- Frazier Life Sciences XI, L.P. - $10.00M of ATTO open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Frequently Asked Questions
What is Deep Track Biotechnology Master Fund, Ltd.?
Deep Track Biotechnology Master Fund, Ltd. is an investment firm, tracked as 10% Owner of Attovia Therapeutics, Inc. (ATTO). InsiderAlpha holds 6 primary Form 4 filings for it, the earliest from 2025, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Deep Track Biotechnology Master Fund, Ltd. submitted recently?
2 primary Form 4 filings in the last 90 days, covering 2 companies.
Has Deep Track Biotechnology Master Fund, Ltd. been buying or selling stock?
Recorded transactions: 5 open-market purchases ($60.00M) and 2 open-market sales ($22.35M) across all tracked filings.
How accurate is Deep Track Biotechnology Master Fund, Ltd.'s historical track record?
Across 4 tracked purchases, Deep Track Biotechnology Master Fund, Ltd. averaged -1.1% avg 30-day return with a 50% 30-day win rate. InsiderAlpha rates the track record at 2/5 stars.
Where can I see all of Deep Track Biotechnology Master Fund, Ltd.'s SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Follow Deep Track Biotechnology Master Fund, Ltd. and every insider like them
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial